Yuki Oya
Last active: 10/27/2015

Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells.

Isono K, Jono H, Ohya Y, Shiraki N, Yamazoe T, Sugasaki A, Era T, Fusaki N, Tasaki M, Ueda M, Shinriki S, Inomata Y, Kume S, Ando Y
Stem Cell Res. 2014 12 (2): 574-83

PMID: 24531302 · DOI:10.1016/j.scr.2014.01.004

Familial amyloidotic polyneuropathy (FAP) is a hereditary amyloidosis induced by amyloidogenic transthyretin (ATTR). Because most transthyretin (TTR) in serum is synthesized by the liver, liver transplantation (LT) is today the only treatment available to halt the progression of FAP, even though LT is associated with several problems. Despite the urgent need to develop alternatives to LT, the detailed pathogenesis of FAP is still unknown; also, no model fully represents the relevant processes in patients with FAP. The induction of induced pluripotent stem (iPS) cells has allowed development of pluripotent cells specific for patients and has led to useful models of human diseases. Because of the need for a tool to elucidate the molecular pathogenesis of FAP, in this study we sought to establish heterozygous ATTR mutant iPS cells, and were successful, by using a Sendai virus vector mixture containing four transcription factors (Oct3/4, Sox2, Klf4, and c-Myc) to reprogram dermal fibroblasts derived from FAP patients. Moreover, FAP-specific iPS cells had the potential to differentiate into hepatocyte-like cells and indeed expressed ATTR. FAP-specific iPS cells demonstrated the possibility of serving as a pathological tool that will contribute to understanding the pathogenesis of FAP and development of FAP treatments.

Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

MeSH Terms (7)

Amyloid Neuropathies, Familial Animals Female Humans Induced Pluripotent Stem Cells Mice Prealbumin

Connections (1)

This publication is referenced by other Labnodes entities: